Pharmaceutical USA-based Genentech, wholly-owned by Swiss drug major Roche, says that theFood and Drug Administration has approved Avastin (bevacizumab) plusinterferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer. According to the American Cancer Society, kidney cancer is the eighth most commonly diagnosed cancer in the United States. In 2009, approximately 13,000 Americans will die from the disease. 4 August 2009